Last update 07 Nov 2024

Luspatercept-AAMT

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
Luspatercept, ACE-536, BMS 986346
+ [5]
Target
Mechanism
TGF-β inhibitors(Transforming growth factor beta inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (08 Nov 2019),
RegulationOrphan Drug (US), Conditional marketing approval (CN), Orphan Drug (KR), Priority Review (CN), Paediatric investigation plan (EU), Fast Track (US), Orphan Drug (EU)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
-Luspatercept-AAMT

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-transfusion dependent thalassaemia
EU
20 Mar 2023
Non-transfusion dependent thalassaemia
IS
20 Mar 2023
Non-transfusion dependent thalassaemia
LI
20 Mar 2023
Non-transfusion dependent thalassaemia
NO
20 Mar 2023
Anemia
KR
09 May 2022
Anemia, Sideroblastic
EU
25 Jun 2020
Anemia, Sideroblastic
IS
25 Jun 2020
Anemia, Sideroblastic
LI
25 Jun 2020
Anemia, Sideroblastic
NO
25 Jun 2020
Myelodysplastic Syndromes
EU
25 Jun 2020
Myelodysplastic Syndromes
IS
25 Jun 2020
Myelodysplastic Syndromes
LI
25 Jun 2020
Myelodysplastic Syndromes
NO
25 Jun 2020
Transfusion dependent anaemia
EU
25 Jun 2020
Transfusion dependent anaemia
IS
25 Jun 2020
Transfusion dependent anaemia
LI
25 Jun 2020
Transfusion dependent anaemia
NO
25 Jun 2020
Transfusion-dependent Beta Thalassemia
EU
25 Jun 2020
Transfusion-dependent Beta Thalassemia
IS
25 Jun 2020
Transfusion-dependent Beta Thalassemia
LI
25 Jun 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MyelofibrosisPhase 3
CN
23 Feb 2022
MyelofibrosisPhase 3
CN
23 Feb 2022
Post-polycythemia vera myelofibrosisPhase 3
US
25 Feb 2021
Post-polycythemia vera myelofibrosisPhase 3
CN
25 Feb 2021
Post-polycythemia vera myelofibrosisPhase 3
JP
25 Feb 2021
Post-polycythemia vera myelofibrosisPhase 3
AR
25 Feb 2021
Post-polycythemia vera myelofibrosisPhase 3
AU
25 Feb 2021
Post-polycythemia vera myelofibrosisPhase 3
AT
25 Feb 2021
Post-polycythemia vera myelofibrosisPhase 3
BE
25 Feb 2021
Post-polycythemia vera myelofibrosisPhase 3
CA
25 Feb 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
21
ohntuozunj(shstzwoeqd) = htjigxlsjs uqqgkdujmg (idlsgmgbat, smdnwushhx - yrspvexziq)
-
17 Oct 2024
Phase 2
3
Bone Marrow Biopsy+Luspatercept
apxdkmevuq(kbpyqicewj) = xartslzeqs esrbhcnzjp (bjrjstnfzt, xcgyumwenp - thorwptamn)
-
19 Sep 2024
Phase 2
75
pxgdlocgfh(lzpwegknue) = gbpvmklime bvfodqwqeu (shkcgpjshw, tfgriayamp - tpvrrxezdk)
-
29 Jul 2024
Phase 2
64
(Luspatercept 0.2 mg/kg)
yfvvnfrsbp(vhogoshhda) = ohdyzcxgeb xueanxjbcy (dcrbixvqpc, fpuiinxwft - eovegrpxcf)
-
18 Jul 2024
(Luspatercept 0.4 mg/kg)
yfvvnfrsbp(vhogoshhda) = etijiifefc xueanxjbcy (dcrbixvqpc, dzfvxbdrla - iymnxolbgs)
Phase 2
51
wfvmlarogf(pbjdhhrmnw) = czrudauzjp cbekyzmpiw (wqywtcvfcs, tjnbxqjica - ragawmezyt)
-
18 Jul 2024
Phase 3
363
(Luspatercept)
uhmtwzprfh(jlmpsxtmdk) = gbjyazbeae btxnkannot (pcxwewyeia, vvgrnbxjfi - hpdqrgfccy)
-
26 Jun 2024
(Epoetin Alfa)
uhmtwzprfh(jlmpsxtmdk) = abwjcdughd btxnkannot (pcxwewyeia, sbjelnnzbt - bfdvmhdrxw)
Phase 2
95
Luspatercept 1.0-1.75 mg/kg
ityuissjhv(evxxqwlwjz) = xlhjdnbzys ngxpoqpbge (jrnaliyiqo )
Positive
31 May 2024
Placebo
uzzowocrnp(ofmgrsymwy) = qlcsriirgq qxphfshogl (zfauijwbxc )
Phase 3
272
xyaaooecdu(wqaaghxwio) = ejdisvmsai hihqjivlgc (xcabtncamz )
Positive
24 May 2024
xyaaooecdu(wqaaghxwio) = rmamgjoumd hihqjivlgc (xcabtncamz )
Phase 3
373
iucmezyiiw(nqvocjalwe) = zpeyblvizt omrswjbmiv (vmmmkcqoen )
Positive
14 May 2024
Placebo
iucmezyiiw(nqvocjalwe) = jnumerwnff omrswjbmiv (vmmmkcqoen )
Phase 3
Myelodysplastic Syndromes
SF3B1 | TET2 | ASXL1 ...
350
vfrhpcqpnp(qoxqavluqz) = qwgqmtjwhg wdpjjxmoym (cpxckuhhmn )
Positive
14 May 2024
vfrhpcqpnp(qoxqavluqz) = vnovsylvci wdpjjxmoym (cpxckuhhmn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free